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Induction of a primary human cytotoxic T-Iymphocyte
response against a novel conserved epitope in a
functional sequence of HIV-1 reverse transcriptase
Sjoerd H. van der Burg*t, Michel R. Klein*, Cornelis J.H. van de Veldet,
W. Martin Kast*, Frank Miedema* and Cornelis J.M. Melief*
Objective: To identify novel major histocompatibility complex (MHC) class l-restricted
cytotoxic T-lymphocyte (CTL) epitopes conserved in HIV-1.
Methods: Potential conserved CTL epitopes were selected using a predictive computer
algorithm based on a human leukocyte antigen (HLA)-A*0201 peptide-binding motif
and tested for actual binding to the human processing defective cell line 174.CEM T2
(T2). Hence, the amino-acid sequences of 14 full-length sequenced HIV-1 strains were
analysed. An in vitro primary peptide-specific human CTL response was induced with
responding lymphocytes of an HIV-1-seronegative donor. Responding T cells were
cloned by limiting dilution and tested for their ability to recognize naturally processed
antigen in a 51Cr-release assay using recombinant vaccinia-HIV protein-infected
B-lymphoblastoid cells (B-LCL) as target cells.
Results: The analysis of peptides bearing the HLA-A*0201 motif for conservation
resulted in one peptide of Env, three of Gag and 12 of Pol. Only Gag340_34g, Pols3_92;
Pol267_277
 ancl p°l96u-%8 showed binding properties to T2 comparable with those of
known CTL epitopes Gag7^e4 SLYNTVATL and Pol458_476 ILKEPVHGV. A successful
primary MHC class l-restricted CTL response was induced against Pol46g_^76
and Pol267_277 VLDVGDAVFSV, a peptide in a functional sequence of reverse
transcriptase (RT). The resulting CD8+ CTL clones were peptide-specific and able
to specifically lyse recombinant vaccinia-HIV-1 RT-infected HLA-A*0201-matched
B-LCL.
Conclusion: The method used to screen proteins sequences for potential CTL epitopes,
test selected peptides for binding to MHC class I and induction of an in vitro primary
response against optimal binding peptides resulted in the identification of at least
one novel conserved CTL epitope. The novel epitope is located in an area crucial
for RT activity. This study demonstrates the feasibility of identifying highly conserved
HIV-1-derived peptides capable of eliciting novel anti-HIV-1 CTL responses.
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Cytotoxic T-cell responses against virus-infected cells are
of key importance in the clearance and control of most
virus infections [1]. Cytotoxic T lymphocytes (CTL)
recognize viral peptides presented by major histocompat-
ibility complex (MHC) class I molecules at the surface of
infected cells [2—6]. CTL responses against many viruses
involve recognition of a single or few immunodominant
viral epitopes [7-9]. However, studies of CTL specific
for HIV-1 have shown that multiple epitopes of all pro-
teins of HIV-1 may serve as targets and that these epi-
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topes can be presented by the same restricting human
leukocyte antigen (HLA) class I molecule [10-13], To
date there has been no systematic study to determine to
which of these peptides an HIV-seropositive individual
responds. The initial vigour of the CTL response against
HIV-1 in infected individuals is shown by CTL activity
of freshly isolated peripheral blood mononuclear cells
(PBMC) without restimulation [13]. Despite these initial
CTL responses, HIV-1 infection nevertheless leads to
virus persistence and eventually to deterioration of hu-
moral and ceUular immune responses [14—16], resulting
in AIDS [17].
One role of CTL in eradicating HSV-infected human
cells was shown in studies in which in vitro HIV-1 repli-
cation was controlled by MHC class I-restricted CTL
[18,19]. Studies of SIV-infected macaques showed that
animals with broad CTL activity were able to control
disease in contrast to SIV-infected macaques with low
CTL activity [20,21]. In HIV-1-infected asymptomatic
individuals effective CTL responses were found against
relatively or highly conserved sequences of HIV-1 Gag
[10,22,23], reverse transcriptase (RT) [24] and Nef [25].
HIV-1 exhibits sequence variation due to error-prone
RT, recombination and the absence of an error-correc-
tion system [26]. Consequent to this lack of control,
the number of virus variants increases with disease pro-
gression [27]. In longitudinal studies a decline or loss of
CTL responses to a particular epitope was found asso-
ciated with the emergence of epitope-loss virus variants
[28,29]. Also, in a comparison of CTL reactivity to an
epitope of one particular HIV-1 virus with natural vari-
ants of this epitope in other HIV-1 viruses, a decrease or
absence of cytotoxicity against peptide-incubated targets
was observed [30]. These results combined with those
of CTL studies in long term asymptomatic individuals
suggest that CTL capable of controlling HIV-1 infection
are directed against epitopes that are not readily prone
to mutation. Strong and sustained CTL responses against
these highly conserved sequences might enable the in-
fected host to effectively control the spread of virus or to
establish at least a low grade of infection so that disease
progression is delayed.
Conservation of protein sequences may reflect functional
importance in the life cycle of the virus. Since HLA-
A*0201 is found at high frequency in all human races
[31], we selected HLA-A*0201-binding peptides that
were completely conserved among different HIV-1 virus
strains. In vitro induction of peptide-specific class I-re-
stricted primary CTL responses has been achieved in
the mouse [32,33] as well as in human [34] systems. We
used the processing-defective ceil line T2 [35] to detect
binding of the selected peptides [36], and a modified
strategy as described by Houbiers et al. [34] to induce
primary CTL responses.
This study demonstrates that novel CTL epitopes in con-
served HIV sequences can be identified by the strat-
egy of in vitro primary immune response induction by
HLA-A*0201 motif-bearing peptides with proven bind-
ing ability to HLA-A*0201.
Materials and methods
Cell lines and recombinant vaccinia viruses
The processing defective T2 cell line, which expresses
low levels of surface HLA-A*0201, was a gift from
Dr P. Cresswell (Yale University, New Haven, Con-
necticut, USA). Recombinant vaccinia constructs were
kindly provided by Dr B. Moss (National Institute of
Allergy and Infectious Diseases, National Institutes of
Health, Bethesda, Maryland, USA). The recombinant
vaccinia virus vCF-21 contains the HlV-l^xitë J">' R-T
gene (wRT) [37]. The negative control recombinant
vaccinia virus vSC-8 contains the Escherichia coli fi-gal
gene (wLacZ) [38].
Cytotoxicity of CTL against target cells was tested in
a standard 4-h 5'Cr-release assay. HLA-A*0201-positive
B-LCL served as target cells. B-LCL were subtyped with
an HLA-A*0201 alloreactive CTL clone [39]. Briefly,
B-LCL were either labelled for l h at 37°C with 100 |iCi
5lCr and preincubated for 10 min with peptide, or tar-
get cells were infected (multiplicity of infection, 5) with
appropriate recombinant vaccinia constructs 16 h before
labelling. A difference of >10% with background lysis
was considered to be specific lysis of target cells. The
percentage-specific 51Cr release was calculated by the
formula:
% specific 5I Cr release =
(release experimental well - background release)
(maximum release—background release)
Xi00%
Target cell lysis by CTL was blocked by incubation of
CTL with anti-CD8 monoclonal antibody (MAb) FK18
[40]. FK18 was used as a 1:300 dilution of ascitic fluid.
Effector cells were mixed with FK18 and preincubated
for l h at room temperature. MHC class I restriction was
determined by 30 min preincubation of T2 cells with
anti-HLA class I MAb W6/32.
Peptide selection and T2 peptide-binding assay
All amino-acid sequences of 14 different full-length se-
quenced HIV-1 virus strains: LAI, MN, NL43, OYI,
SF2, RF, MAL, D31, CAM1, HAN, ELI, NDK, JR-
CSF and JR-FL [41] were screened for possible HLA-
A*0201-restricted CTL epitopes using a scoring sys-
tem [36]. Virus strains not full-length sequenced or
the highly divergent Cameroonian isolates were not in-
cluded. All predicted high-scoring peptides were com-
pared and those sequences with anchor residues on both
anchor positions and completely conserved among all 14
strains were synthesized as described previously [34].
The T2 HLA-A*0201 peptide-binding assay was per-
formed according to Nijman et al. [36]. Fluorescence
CTl induction to novel epitopes of HIV-1 van der Burg et at. 123
of viable cells was measured on a FACscan flow cy-
tometer (Becton Dickinson, Franklin Lakes, New Jersey,
USA). The fluorescence index (FI) was calculated by the
formula: FI =(mean fluorescence sample—mean fluores-
cence background) -s- mean fluorescence background.
Peptides with a FI>0.5 were considered to bind to
HLA-A*0201. Subsequent serial dilutions of the con-
centration of peptide were used to determine the con-
centration needed to upregulate HLA-A*0201 to half
maximum fluorescence on the T2 cell line.
Primary CTL induction
The in vitro CTL response induction method recently
published [34] was modified as follows. T2 cells were
loaded with 100|ig/mi peptide overnight at 37°C and
subsequently treated with 50 Hg/ml Mitomycin-C (Ky-
owa Co. Ltd, Tokyo, Japan). After 2 h the cells were
washed twice and used as antigen-presenting cells by
cocultivation with HLA-A*0201 -positive PBMC of a
healthy HIV-1-seronegative donor at a T2-to-PBMC
ratio of 1:4. Cells were cultured for 10 days in
2ml standard medium [RPMI-1640 Dutch modifica-
tion (Gibco, Paisley, Scotland, UK) containing L-glu-
tamine, antibiotics, 15% pooled human serum] and
40 Hg/ml peptide in 24-well Costar plates (Costar, Cam-
bridge, Massachusetts, USA) at a density of 2 million
cells/well. Responder cells were harvested and depleted
of CD4+ T cells using CD4+ magnetic beads (Dynal
A.S, Oslo, Norway). Two million CD4-depleted respon-
der cells were restimulated with a feeder-mix consist-
ing of 1x106 irradiated (3000 rad) autologous PBMC
and 2xl05 irradiated (10 000 rad) autologous B-LCL.
Feeder cells were sensitized with 50 pig/ml peptide in
serum-free Iscove's modified Dulbecco's medium for 2 h
at 37°C, washed and added to the responders in stan-
dard medium supplemented with 60IU/ml human re-
combinant interleukin-2 (rIL-2; Eurocetus, Amsterdam,
The Netherlands). At day 17, responder cells were har-
vested on Ficoll-lymphoprep (Nycomed Pharma, Oslo,
Norway) and cloned by limiting dilution. Ten or less
responder cells were cocultured with 1 X105 irradiated
(3000rad) PBMC and 5000 irradiated (10000 rad), pep-
tide sensitized washed B-LCL (from at least two dif-
ferent HLA-A*020l-positive donors) in 100 nj standard
medium containing 60 IU rIL-2/ml and 1% leucoagglu-
tinin (Phytohaemagglutinin-leucocytes; Sigma, St Louis,
Missouri, USA). Growing clones were expanded but
stimulated with peptide-sensitized washed B-LCL at a
2-week interval only.
Results
Selection of conserved HIV peptides with binding
ability for HLA-A*0201
Analysis of binding to HLA-A*0201 of the amino-acid
sequences of Env, Gag, Pol, Rev, Vpu, Vif, Vpr, Tat
and Nefof 14 full-length HIV-1 strains resulted in one
conserved peptide of Env, three of Gag, and 12 of Pol
bearing the HLA-A*0201 motif. The binding capacity
of these peptides was tested in the T2-binding assay. Five
out of 16 peptides had a FI > 0.5 at a concentration of
lOOilg/ml. Subsequent binding tests with serial dilu-
tions of the peptide concentration revealed high affinity
binding of one Gag peptide (Gag345_3j3), and three Pol
peptides (Pol83_92, Pol267-277>
 pol96<>-968; T*b\e 1). As a
control, the serial dilutions of two known CTL epitopes
Pol468^t76 ILKEPVHGV [42] (highly conserved) and
Gag77_g5 SLYNTVATL (not conserved) [43] resulted in
a half maximum of 5 and 20 [ig/ml, respectively (Table
1). In accordance with earlier studies [36], 60% of the
motif-bearing peptides did not bind.
Table 1. Binding of conserved HIV-1 sequences of Gag, Pol and Env to























































































*Derived from HIV-1 strain |R-CSF. ^The peptides Pol468_476 [42] and
Gag77_o5 [433 are known HLA-A*020i-restricted cytotoxic T-lymphocyte
epitopes, therefore, the half of maximum (V; max} fluorescence values
obtained with these pepïides served as reference for good binding. Com-
puter scoring of predicted HLA-A*U2G1-binding peplides was performed
according to Nrjman et al. (36]. The importance of the anchor positions
was stressed by assigning 12 points to ailowed residues at these positions
[36]. The fluorescence index (FI) is shown at lOOjog/ml ol' pepticie: pep-
lides wllh a FI >0.5 were considered to be binding peptides. The affinity
of binding peptides was tested by determining the peptide concentration
needed to upregulate HLA-A*0201 expression on the T2 cell line to Va
max fluorescence: peptides with Y2 max >two times the Vj max of pep-
tide Gag76_fl4 were considered to be weakly binding peptides.
Induction of primary CTL responses
We induced primary CTL responses against the peptides
Pol267-277 and Pol46«^76 (Table 1) from PBMC of a
HIV-1-seronegative healthy donor. The known HLA-
A*G201 -restricted peptide Pol468^76 was selected as a
positive control for CTL induction. Limiting dilution
resulted in clones 468-13, 468-16 and 468-22 against
peptide Pol4f$_476 and clone 267-18 against peptide
Pol267-277 showing specific lysis of T2 cells sensitized
with peptide (Fig. 1).
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Fig. 1. Lytic activity of clones 468-13 (B, 468-16 O and
468-22 (O) obtained against peptide Pol468_476 and clone
267-18 (•) against peptide Poli67_277 was tested against
peptide-foaded T2 cells. T2 cefls were pre-incubated for
10 min with increasing concentrations (pmol/ml) of specific
peptide and then used as targets. The percentage lysis of T2
cells is represented as the percentage-specific 5ir_r-release
values and shows for each clone the mean of triplicate meas-
urements at an effector-to-target ratio of 5 :1 for Pol46a_476
and 10:1 for Pol267-277 obtained in two independent exper-
iments.
FACscan analysis showed that the clones were CD8-pos-
itive. Blocking studies with anti-CD8 or anti-HLA class
I antibodies revealed that CTL activity was mediated by
CD8+ T cells and was HLA class-1-restricted (data not
shown).
The clones were tested at different effector-to-target cell
(E:T) ratios to estimate the cytolyn'c capacity. At an
E :T ratio of 0.015 for clone 267-18 and 0.15 for clone
468-22, T2 cells sensitized with 5nm/ml of peptide are
specifically lysed (data not shown).
The fine specificity of clone 267-18 was studied by ser-
ine and arginine replacements in the synthetic Pol267_277
peptide. Binding of the peptide was strongly influenced
by the residues at position 2 and 11. Replacement by a
small amino acid such as serine showed that residues 3, 4,
5, 8 and 9 in particular are important for recognition by
the CTL. Arginine replacement had more drastic effects
in that only a replacement at position 6 allowed recog-
nition of peptide-sensitized target cells (data not shown).
Thus, residues at positions 3, 4, 5, 8, 9 and 10 interfere
with recognition by the T-cell receptor.
Recombinant vaccinia virus-infected target cells
To investigate whether the clones would not only rec-
ognize synthetic peptide but also the naturally processed
Fig. 2. Recognition of target cells sensitized by exogenously
added peptide and of target cells expressing the natural pro-
cessed epitope by clone 267-18 (left) and clone 468-22
(right), (a) B-lymphoblastoid cells (B-LCU were infected with
recombinant vaccinia-HIV-1 reverse transcriptase (vvRT; ~)
gene. Aspecific lysis of the B-LCL due to vaccinia infec-
tion was monitored by infecting B-LCL with recombinant
vaccinia-B-ga/ (vvLacZ; • gene, (b) Aspecific lysis of the 8-
LCL by the cytotoxic T-lymphocyte clones was also tested.
The specific lysis of 5 u.g/rnl peptide-pulsed B-LCL O versus
background lysis of non-peptide-pulsed B-LCL W is shown.
The clones were tested at different effector-to-target (E: T) ra-
tios and the percentage-specific lysis of different targets is
represented as percentage-specific 51Cr-release values and
show for each clone the mean of triplicate values obtained
in two independent experiments.
peptide, the most sensitive CTL clones were tested
against B-LCL infected with the recombinant vaccinia
viruses wRT or wLacZ. Clones 468-22 and 267-18
lysed wRT but not wLacZ-infected B-LCL (Fig. 2a).
In the same experiments both clones specifically lysed
peptide-sensitized HLA-A*0201-matched B-LCL (Fig.
2b).
Discussion
The therapeutic potential of CTL against tumours and
viruses has recently been reviewed [1,12,13,44]. The im-
minent escape of HIV-1 from deteriorating humoral and
cellular immune responses requests prompt and specific
intervention. Evoking CTL to highly conserved HIV-
1-derived epitopes may decrease the risk of emerging
escape mutants of HIV-1, which may contribute to the
control of HIV-1 infection.
Following our strategy to screen protein sequences for
potential CTL epitopes, test selected peptides for MHC
class I binding, and induce CTL against the optimally
binding peptides resulted in CTL recognizing naturally
processed HIV-1-derived peptides, including one novel
RT epitope in a protein sequence crucial for RT activity.
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The existence of CD4+ CTL in HIV patients [45,46]
is acknowledged but CD4+ T cells are more suscepti-
ble to HIV infection and compared with CD8+ CTL,
display lysis of HIV-infected cells only at higher E: T
ratios [45]. In vitro it is possible to infect CD8+ T cells
[47,48]. The in vim relevance of this phenomenon is
debatable because HIV-1 DNA was not detectable by
polymerase chain reaction (PCR) in the CD8+ subset
of PBMC from AIDS patients [49]. Therefore we have
focused primarily on induction of HIV-specific CD8+
CTL.
One Gag and three Pol peptides showed similarly high-
affinity binding properties as previously published HLA-
A*0201-restricted CTL epitopes [42,43]. Analysis of the
Gag sequences of 70 HIV-1 isolates [50] showed the
high conservation of the binding Gag345_353 peptide in
63 out of 70 isolates. It is noteworthy that CTL from
a long-term asymptomatic HIV-1-seropositive individ-
ual reacted to target cells pulsed with a 20 amino-acid
peptide containing this Gag345_353 peptide [15].
Induction of primary CTL responses to peptides in
vitro has already been shown in mice [51] and humans
[34,52]. Our in vitro induction protocol, using PBMC
from a healthy HIV-1-seronegative blood donor, al-
lowed generation of CTL to a novel highly conserved
HLA-A*0201-restricted epitope (Pol267-277: VLDVG-
DAYFSV) derived from HIV-1 pol RT. We also elicited
a primary CTL response to the already known HLA-
A*0201-restricted epitope, published by Walker et at.
(Pol46g_J|76) [42]. The resulting CD8+ CTL clones were
able to recognize target cells pulsed with as little as 10
pmol peptide/ml. Observations in mice of CTL against
influenza nucleoprotein showed recognition of peptide
at concentrations of 0.1-100 pmol peptide/ml [2,3].
Clones 468-22 and 267-18 both directed to RT epi-
topes were able to specifically kill recombinant vaccinia
HIV-1 RT-infected targets in a class I-restricted fash-
ion. Although 5'Cr release is lower it is frequently ob-
served that the lower peptide concentration displayed at
the cell surface following endogenous processing is often
associated with lower 51Cr-release values than following
incubation with much higher doses of exogenous pep-
tide. In a recent study from our laboratory [53], low
in vitro tumour lysis values following incubation with
tumour-specific CTL was nevertheless associated with
CTL-mediated protection against tumour outgrowth in
vivo [53]. Thus, the lower CTL response measured in vitro
against the endogenously processed peptide provided ad-
equate protection in vivo [53]. An overall difference in
the maximum percentage of lysis can be noticed between
clones 267-18 and 468-22. This could be due to a dif-
ference in lytic capability of the clones although both
clones lysed their targets at similar E : T ratios. The lysis
of wRT-infected cells is similar when compared with
the background lysis of wLacZ-infected cells. On the
other hand, variation in peptide affinity can exist be-
tween different CTL recognizing the same epitope [2,3].
It will be of interest to study the possible diversity of the
T-cell repertoire against epitope Pol267-277-
Sequences in which no variation is allowed due to func-
tional or structural constraints on the viral protein may
offer CTL an opportunity to attack HIV-1 at its Achilles'
heel. The RT-derived peptide Pol267~277 "^Y therefore
be a particularly interesting epitope. Site-specific mu-
tagenesis of the region overlapping peptide Pol267-277
revealed that alterations in the sequence by substitution
of single amino acids at position 269 (asp to glu}, 272
(asp to gly) or 273 (ala to ser) can profoundly affect
RT activity [54]. All of these amino acids are located in
peptide Pol267_277- The amino-acid replacement study
showed that among six of the amino-acid side chains
the aspartic acid at position 269 was also important for
recognition by clone 267-18. The amino acids at po-
sitions 3, 4, 5, 8, 9 and 10 seem essential for T-cell
receptor recognition, which largely confirms previous
reports on HLA-A*0201-restricted CTL [8,34,55]. Viral
escape from T-cell recognition by mutation of the T-cell
receptor contact residues [28,56] could be disastrous for
the virus in the case of the Pol267_277 epitope.
Recently Harrer et al. [24] reported a study of anti-
HIV CTL responses in long-term asymptomatic HIV-
seropositive individuals. A response was found against a
CTL epitope that spans the RT region of the highly con-
served YMDD amino-acid motif also known to be im-
portant for RT function [54,57]. Targeting the immune
response to this epitope, the epitope identified in this
study and others found in regions that are functionally
important for the life cycle of HIV-1 may influence the
length of the asymptomatic phase.
Our data show the feasibility of primary in vitro targeting
to a synthetic viral peptide of human CTL capable of
recognizing the naturally processed peptide. Recently,
induction of primary CTL in a completely autologous
system was reported [52]. These approaches may allow in
vitro culture of CTL against a viral or autologous peptide
of interest for adoptive transfer into patients with viral
disease or cancer. Primary CTL induction with lym-
phocytes obtained from HIV-infected subjects has to be
established. We are currently investigating this possibil-
ity with PBMC obtained from long-term asymptomatic
patients.
A study by Sijts et al. [58] in mice showed the rel-
evance of cryptic epitopes: upon infection with the
Moloney sarcoma virus-murine leukaemia virus com-
plex C57BL/6 mice (H2b) respond with a class I D>>-
restricted CTL response but peptide vaccination with a
Kb-restricted epitope resulted in CTL recognizing this
epitope both as synthetic peptide and as endogenously
processed antigen in the context of K^. It is therefore
feasible to direct the cellular immune response to sub-
dominant epitopes that are not selected as major epi-
topes for CTL recognition. It can be argued that im-
munization with peptides might result in relatively low
responses in vitro and that peptide immunization might
therefore result in weak responses in vivo. However, in
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vivo peptide immunization could result in higher levels of
specific CTL because the proper cytokine networks and
lymphoid architecture are available. In animal models it
has been shown that peptide immunization can effec-
tively protect against lymphocytic choriomeningitis virus
[9], Sendai virus [7] and human papilloma virus-induced
tumours [53]. A peptide-based vaccine also elicited pro-
tective CTL in rhesus monkeys against SIV [59].
The exquisite sensitivity of CTL to sequence variation
in the epitope itself demonstrates the need for stable
epitopes. Thus peptide vaccines should be designed to
evoke immune responses against several of these func-
tionally important epitopes in order to minimize the
emergence of escape variants of the virus.
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